Clinical Trials Browser

Phase 1/2 × lorukafusp alfa × 1 year × Clear all

NCT03958383 2025-04-18

IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma

Phase 1/2 Active not recruiting

Melanoma